Cryoport, Inc. (NASDAQ:CYRX) Director Sells $108,688.05 in Stock

Cryoport, Inc. (NASDAQ:CYRXGet Free Report) Director Richard J. Berman sold 8,105 shares of Cryoport stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $13.41, for a total transaction of $108,688.05. Following the transaction, the director now owns 100,000 shares in the company, valued at approximately $1,341,000. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Cryoport Stock Performance

NASDAQ:CYRX opened at $12.65 on Friday. The company’s fifty day moving average price is $16.32 and its 200-day moving average price is $15.38. Cryoport, Inc. has a 1-year low of $9.00 and a 1-year high of $23.50. The company has a current ratio of 10.73, a quick ratio of 10.22 and a debt-to-equity ratio of 0.86.

Cryoport (NASDAQ:CYRXGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The company had revenue of $54.59 million for the quarter, compared to analysts’ expectations of $58.78 million. Cryoport had a negative net margin of 50.17% and a negative return on equity of 15.19%. The business’s revenue for the quarter was down 13.1% on a year-over-year basis. During the same period in the previous year, the business earned ($0.16) earnings per share. As a group, analysts anticipate that Cryoport, Inc. will post -1.37 EPS for the current year.

Hedge Funds Weigh In On Cryoport

A number of institutional investors have recently bought and sold shares of the company. Cadian Capital Management LP raised its stake in shares of Cryoport by 298.2% in the 3rd quarter. Cadian Capital Management LP now owns 2,656,739 shares of the company’s stock valued at $36,424,000 after acquiring an additional 1,989,598 shares during the period. Assenagon Asset Management S.A. increased its stake in Cryoport by 487.7% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,393,156 shares of the company’s stock worth $21,580,000 after buying an additional 1,156,106 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Cryoport by 46.9% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock worth $30,870,000 after acquiring an additional 636,395 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Cryoport during the 1st quarter worth approximately $7,800,000. Finally, New York State Common Retirement Fund boosted its holdings in shares of Cryoport by 29.9% in the 4th quarter. New York State Common Retirement Fund now owns 1,642,752 shares of the company’s stock valued at $25,446,000 after buying an additional 378,340 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CYRX has been the topic of a number of analyst reports. Jefferies Financial Group initiated coverage on shares of Cryoport in a research note on Thursday, April 4th. They set a “buy” rating and a $21.00 target price on the stock. UBS Group lifted their target price on shares of Cryoport from $14.50 to $17.00 and gave the company a “neutral” rating in a research note on Friday, March 15th. B. Riley cut shares of Cryoport from a “buy” rating to a “neutral” rating and lowered their target price for the company from $22.00 to $19.00 in a research note on Friday, May 3rd. Stephens restated an “equal weight” rating and set a $17.00 target price on shares of Cryoport in a research note on Wednesday, March 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target on shares of Cryoport in a report on Wednesday, May 8th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $18.25.

Read Our Latest Research Report on CYRX

About Cryoport

(Get Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

See Also

Insider Buying and Selling by Quarter for Cryoport (NASDAQ:CYRX)

Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with's FREE daily email newsletter.